# Varicella Zoster Virus glycoprotein E

## Shingrix inj 0.5mL/dose

| TAH Drug Code      | [ISHG](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISHG)                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of herpes zoster (HZ) in adults aged 50 years and older or in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.                                                                                                            |
| Dosing             | IM only. Two doses (0.5 mL/dose) in total. A first dose at Month 0 followed by a second dose administered 2-6 months later. For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1-2 months later. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.                                                                                                                                                                                                                  |
| Adverse Effects    | Pain (78%), redness (38%), swelling (26%), myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)                                                                                                                                                                                     |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/varicella-zoster-virus-glycoprotein-e-drug-information)                                                                                                                                                                                                                                           |

